Singapore markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
41.97+0.18 (+0.43%)
At close: 04:00PM EDT
41.80 -0.17 (-0.41%)
After hours: 07:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close41.79
Open41.68
Bid41.93 x 200
Ask42.02 x 200
Day's range41.25 - 42.19
52-week range22.11 - 53.18
Volume510,304
Avg. volume958,318
Market cap2.757B
Beta (5Y monthly)1.51
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

    HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 10:00 a.m. ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media” section of the Celldex website. A replay will be available for 30 days following the event. About Celldex Therapeutics, Inc.Celldex i

  • GlobeNewswire

    Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

    HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen’s 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET. A live webcast of the panel discussion will be available on the investor section of the Celldex website. A replay of the webcast

  • GlobeNewswire

    Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share. All of the shares sold in the offering were sold by Celldex. The gross pro